Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy
PUBLICATION: Ann Surg Oncol (2016) 23: 1522. https://doi.org/10.1245/s10434-015-5030-1. AUTHORS: Paul Read More
Molecular Subtyping Improves Diagnostic Stratification of Patients with Primary Breast Cancer into Prognostically-Defined Risk Groups
PUBLICATION: Breast Cancer Res Treat (2015) 154: 81. https://doi.org/10.1007/s10549-015-3587-9. AUTHORS: Read More
Molecular Subtyping Predicts Pathologic Tumor Response in Early-Stage Breast Cancer Treated with Neoadjuvant Docetaxel Plus Capecitabine with or without Trastuzumab Chemotherapy GalleryMolecular Subtyping Predicts Pathologic Tumor Response in Early-Stage Breast Cancer Treated with Neoadjuvant Docetaxel Plus Capecitabine with or without Trastuzumab Chemotherapy
Molecular Subtyping Predicts Pathologic Tumor Response in Early-Stage Breast Cancer Treated with Neoadjuvant Docetaxel Plus Capecitabine with or without Trastuzumab Chemotherapy
PUBLICATION: Med Oncol. (2014) 31: 163. https://doi.org/10.1007/s12032-014-0163-9. AUTHORS: Soley Bayraktar, Read More
Estrogen Receptor Splice Variants as a Potential Source of False-Positive Estrogen Receptor Status in Breast Cancer Diagnostics
PUBLICATION: Breast Cancer Res Treat (2013) 140:475–484 DOI 10.1007/s10549-013-2648-1 AUTHORS: Read More
Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy
PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):759-67. doi: 10.1007/s10549-013-2572-4. AUTHORS: Read More
Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients
PUBLICATION: Ann Surg Oncol. 2012 Oct;19(10):3257-63. doi: 10.1245/s10434-012-2561-6. Epub 2012 Read More
A Diagnostic Gene Profile for Molecular Subtyping of Breast Cancer Associated with Treatment Response
PUBLICATION: Breast Cancer Res Treat (2012) 133: 37. https://doi.org/10.1007/s10549-011-1683-z. AUTHORS: Read More
